News
The US Food and Drug Administration has named Dr. Vinay Prasad, a hematologist oncologist, to lead its Center for Biologics ...
6d
Axios on MSNVinay Prasad believes that the FDA too often has acted as a rubber stamp for pharma, both big and small.Biotech venture capital is risky business, inherently at the mercy of regulators and binary outcomes. Now it may face a new ...
President Donald Trump unwrapped a massive drug pricing policy as CMS prepares for the next round of Medicare drug price ...
CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...
6dOpinion
MedPage Today on MSNVinay Prasad Speaks to CBER Staff: Which Prasad Showed Up?The question on many minds among FDA rank-and-file in attendance was: Which Prasad would show up? The 2010s Prasad -- a ...
Vinay Prasad will be the next director of the FDA's Center for Biologics Evaluation and Research, after Peter Marks was forced out.
FDA Commissioner Marty Makary named Vinay Prasad, a hematologist oncologist and critic of the Covid-19 vaccine for children, ...
HealthDay on MSN2d
Dr Vinay Prasad to Head FDA Vaccine, Biologics DivisionThe FDA has chosen Dr Vinay Prasad, a professor at UCSF, to lead its Center for Biologics Evaluation and Research.
In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...
8d
Scripps News on MSNDrug industry critic Vinay Prasad will lead FDA's vaccine oversightVinay Prasad will serve as director of the FDA's Center for Biologics Evaluation and Research, which oversees vaccine and ...
The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a professor at the University of California-San Francisco, to lead its Center for Biologics Evaluation and Research.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results